Open AccessHepatitis B in hepatocellular carcinoma patients and its correlation with alpha-fetoprotein and liver enzymes
Author(s) -
DineshKumar Sinha,
Richa Surit,
Ravi Shekhar,
SanjeetKumar Singh,
Upendra Kumar,
Nidhi Prasad
Publication year - 2022
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_239_19
Subject(s) - hepatocellular carcinoma , hbsag , medicine , alkaline phosphatase , gastroenterology , cirrhosis , alpha fetoprotein , hepatitis b virus , hepatitis b , population , immunoassay , enzyme , virus , immunology , biology , antibody , biochemistry , environmental health
Hepatocellular carcinoma (HCC) in India ranges from 0.7 to 7.5 for men and 0.2 to 2.2 for women, per 100,000 population per year. The major risk factors for the development of HCC are infection with hepatitis B virus (HBV), hepatitis C virus, and cirrhosis of liver. Alpha-fetoprotein (AFP) and liver enzymes are widely used by clinicians for diagnostic purpose in HCC.